Skip to content
NKCELLThe NK guide

The biology

How Perforin and Granzymes Work Together

Perforin and granzymes are often described as a two-part killing system. The useful distinction is delivery versus execution—and the lab evidence is narrower than the shorthand suggests.

The short answer: delivery is not the same as execution

Perforin and granzymes are often lumped together as the killing granules, but a cleaner distinction is delivery versus execution. In the in vitro study on granzyme B entry and trafficking, granzyme B is the enzyme whose route into and through a target cell is being tracked, while perforin is the other named component of the apoptosis process under study. Apoptosis is a controlled form of cell death. The NCI Dictionary entry on natural killer cells describes NK cells as immune cells that can kill tumor cells and virus-infected cells, and its entry covers their granules. That describes a cell capability, not a person's cancer protection. The practical warning comes from a different source: in a flow cytometry method article on human NK cells, the authors explicitly note that degranulation is not the same as target-cell lysis. A CD107a readout can indicate degranulation, but it does not by itself prove that a target cell died.

Three sources, three different questions

Swipe or scroll to read the full table →

Source What it supports What it does not show
NCI Dictionary entry on natural killer cells NK cells are immune cells that can kill tumor cells and virus-infected cells; the entry covers their granules. That an individual has a particular level of cancer protection, or that NK-cell activity alone determines an outcome.
Flow cytometry method article on human NK cells CD107a can be used to track degranulation after target-cell stimulation, including with K562 cells, and cytokine readouts can be measured. The authors explicitly say degranulation does not equal target-cell lysis. That a CD107a signal alone proves a target cell was killed, or that an assay result is patient benefit.
In vitro study of granzyme B entry and trafficking The study examined granzyme B entry and trafficking in target cells during granzyme B-perforin-mediated apoptosis. That this is the only way cytotoxic cells kill in the human body, or that the mechanism is a treatment result.

What a granule-release assay can and cannot tell you

Flow cytometry is a lab method for measuring properties of individual cells. The method article on functional analysis of human NK cells describes using CD107a to detect degranulation after stimulating NK cells with target cells such as K562, plus cytokine readouts. That is useful because it lets researchers separate a release step from other functions. But the same article makes the boundary explicit: degranulation is not target-cell lysis. So when a study says NK cells were activated or degranulated, the result may be about granule release, not about a dead target cell. My inference is that the two measurements should be kept separate in any plain-language summary.

Granzyme B has to get inside the target cell

The trafficking study is a mechanism paper, not a clinical trial. Its subject is entry and trafficking of granzyme B in target cells during granzyme B-perforin-mediated apoptosis. In plain terms, the researchers were asking how a granzyme gets into a target cell and where it goes once inside during a perforin-linked death process. This is where 'works together' becomes more precise: granzyme B is the apoptosis-associated enzyme being tracked, and perforin is part of the entry-and-trafficking context under study. That division of labor is an explanatory reading of the study's scope. It does not mean that every cytotoxic granule in every tissue uses exactly this route, or that perforin and granzyme B act alone.

Why one mechanism is not the whole immune response

The NCI Dictionary definition is broad: NK cells can kill tumor cells and virus-infected cells. A single in vitro trafficking experiment cannot carry that whole claim. It can support a mechanism claim: under lab conditions, granzyme B enters and moves through target cells during a perforin-mediated apoptosis pathway. It cannot show that this pathway is the only one, that it is sufficient in every person, or that a lab readout predicts a clinical outcome. My reading is that mechanism stories are clearest when three levels stay separate: molecule, cell, and patient. Molecule-level and cell-level findings can be real and useful; patient-level claims need different evidence.

A clearer way to read the shorthand

Shorthand phrases compress a multi-step process. A more accurate version is this: an immune cell can release granule contents; granzyme B is tracked as an enzyme that enters target cells and is linked to apoptosis; perforin is part of the process being studied; and CD107a can measure degranulation, but that measurement is not the same as target-cell lysis. Each clause comes from a different kind of source, and none of them is a personal medical prediction.

Medical information note: This is general education about cell biology, not medical advice. Lab measurements of immune-cell activity are interpreted in context by qualified clinicians and researchers; a mechanism finding is not a diagnosis, a treatment recommendation, or a measure of an individual's immune strength.

Sources and further reading

Keep reading

Follow the next question.

The biology